Blog

Company News

Industry Trends

Laws Regulations

All Categories >

20

2025-10

One-Stop Complete Solution for γδ T Cell Culture

As an emerging immunotherapy, γδ T-cell immunotherapy has become a new research hotspot due to its unique anti-tumor advantages. γδ T cells exert their anti-tumor effects primarily by secreting pro-apoptotic molecules and inflammatory cytokines, as well as through TCR-dependent mechanisms. Numerous clinical studies have demonstrated that γδ T-cell immunotherapy exhibits good tolerability and efficacy.

2025-10-20

He Yousheng

20

2025-10

Exhibition Invitation | The Inaugural Intelligent Technologies Forum for Drug Discovery and the WeMol User Conference

To mark the 10th anniversary of Weixin Computing, we cordially invite all WeMol platform users and drug discovery experts to gather in Shanghai for the inaugural Intelligent Technologies in Drug Discovery Forum and WeMol User Conference, to be held on November 8, 2025. With the theme “A New Paradigm for AI-Driven Drug Discovery: From Technology Leadership to Value Creation,” the event will feature presentations by numerous distinguished guests showcasing real-world user case studies, a focused exchange on cutting-edge applications of AI-assisted drug discovery, and an exploration of innovative R&D models that integrate computational and experimental approaches. Zhang Yingbo, Head of the Biotechnology Division at Shanghai Hycells, has also been invited to attend this conference.

2025-10-20

He Yousheng

20

2025-10

Exhibition Invitation | IGC2025: The 10th International Conference on Research, Development, and Industrialization of Cells and Derivatives

The 10th IGC 2025 Conference on Cell and Derivative R&D and Industrialization will be grandly inaugurated at the Langham Guangzhou on October 30–31. Leveraging the policy advantages of the Greater Bay Area, this year’s event features a plenary session and four specialized tracks, bringing together experts from more than 60 leading research institutions—including West China Lecity, Xiangxue, Baiji, Dabao, China Resources, Guanhao, Keyi, Beike, Sinovac, Laen, Tiankeya, Qianhui, Elp, Xidi, Ruizhen, Sipu, Ai Yi, and Aixiuma—as well as CEOs of industry-leading companies and partners from prominent investment firms, to jointly explore cutting-edge fields such as in vivo immune cell therapy, MSC/iPSC stem cell therapy, exosome-based therapies, and anti-aging medical aesthetics.

2025-10-20

He Yousheng

15

2025-09

Little “Sheng” Has a Reason Learning Hall | TDCC Experimental Skills Intensive Training Course

With the rapid advancement of cancer immunotherapy, novel therapeutic modalities such as bispecific antibodies, immune cell engagers, and adoptive cell therapies have emerged one after another. A core mechanism underlying these approaches is the redirection and activation of T cells to achieve specific cytotoxicity against tumor cells. The T cell–dependent cellular cytotoxicity (TDCC) assay, regarded as the “gold standard” for in vitro efficacy assessment of such agents, plays a pivotal role in drug screening, mechanistic studies, and preclinical evaluation.

2025-09-15

He Yousheng

21

2025-08

Good News! Hycells Supports Qihan Bio’s Universal CAR-T Therapy in Obtaining FDA Approval!

On August 13, 2025, Qihan Bio, a biotechnology company dedicated to applying high-throughput gene-editing technologies to cell therapy and organ transplantation, announced that its Investigational New Drug application for QT-019B, the company’s first independently developed universal, dual-target CAR-T cell product, has received formal approval from the U.S. FDA. QT-019B is the first universal CAR-T cell product for the treatment of autoimmune diseases that has been independently developed by a Chinese company and granted U.S. FDA clinical trial approval.

2025-08-21

He Yousheng

21

2025-08

Hycells Bio & InnoCell | Integrated Cell Subtype Sorting Solution

Peripheral blood mononuclear cells (PBMCs) are a population of cells in peripheral blood that possess a single nucleus, primarily comprising lymphocytes and monocytes. According to the Biosecurity Law of the People’s Republic of China, which came into effect on April 15, 2021, human-derived samples must be obtained in a lawful and compliant manner. The Innops Human Immune Cell Sorting Kit provides safe and reliable healthy human-derived samples for use as controls.

2025-08-21

He Yousheng
< 1...678...23 >